Docoh
Loading...

GSTC GlobeStar Therapeutics

Filed: 17 May 21, 11:37am

 

UNITED STATES

OMB APPROVAL

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB Number:

Expires:

3235-0058

February 28, 2022

 

 

Estimated average burden hours

 

 

per response

2.50

 

FORM 12b-25

 

SEC FILE NUMBER

000-55072

 

NOTIFICATION OF LATE FILING

CUSIP NUMBER

 


(Check one):

[_] Form 10-K

[_] Form 20-F

[_] Form 11-K

[X] Form 10-Q

[_] Form 10-D

[_] Form N-CEN

[_] Form N-CSR


 

For Period Ended: March 31, 2021

 

 

 

[_]  Transition Report on Form 10-K

 

[_]  Transition Report on Form 20-F

 

[_]  Transition Report on Form 11-K

 

[_]  Transition Report on Form 10-Q

 

For the Transition Period Ended:__________________________________


Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:


PART I — REGISTRANT INFORMATION


AngioSoma, Inc.

Full Name of Registrant

 

719 Jadwin Avenue

Address of Principal Executive Office (Street and Number)

 

Richland, WA 99352

City, State and Zip Code


PART II — RULES 12b-25(b) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)


 

(a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

[X]

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.




PART III — NARRATIVE


The report of the registrant on Form 10-Q for the quarterly period ended March 31, 2021 could not be filed within the prescribed time period because the Company needs additional time to complete the financial statements and to prepare the Form 10-Q. The registrant anticipates that it will require no more than the additional 5 days allowed to complete and file the Form 10-Q.


PART IV — OTHER INFORMATION


(1)

Name and telephone number of person to contact in regard to this notification


 

James C. Katzaroff

 

206

 

451-1970

 

(Name)

 

(Area Code)

 

(Telephone Number)


(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

 

  [X]  Yes

  [_]  No

 

 

 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

  [_]  Yes

  [X]  No

 

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 


 

AngioSoma, Inc.

 

(Name of Registrant as Specified in Charter)


 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date

May 17, 2021

 

By

/s/ James C. Katzaroff

 

 

 

 

James C. Katzaroff, President and CEO